Valuation: CSL Limited

Market Cap 5.84TCr 5TCr 4.66TCr 4.28TCr 8.04TCr 5,58600Cr 8.2TCr 55TCr 22TCr 2,79900Cr 22TCr 21TCr 9,26800Cr P/E 2027 *
20.1x
P/E 2028 * 18.2x
Enterprise Value 6.75TCr 5.78TCr 5.39TCr 4.95TCr 9.3TCr 6,45900Cr 9.48TCr 64TCr 25TCr 3,23700Cr 25TCr 25TCr 10,71700Cr EV / Sales 2027 *
4.3x
EV / Sales 2028 * 4.13x
Free-Float
99.97%
Yield 2027 *
2.46%
Yield 2028 * 2.61%
Manager TitleAgeSince
Chief Executive Officer 63 11/02/2026
Director of Finance/CFO 52 07/10/2025
Chief Operating Officer - 01/05/2025
Director TitleAgeSince
Director/Board Member 72 17/10/2018
Director/Board Member 70 02/02/2011
Director/Board Member 71 09/12/2019
Change 5-day change 1-year change 3-year change Capi.($)
-1.69%+3.59%+44.57%+1.75% 8.4TCr
-23.55%+109.39%+377.68%+31.19% 6.96TCr
+2.84%+23.66%-24.08%-36.73% 5.68TCr
+1.94%+1.61%-0.03%+32.78% 5.14TCr
+0.05%-1.76%+13.19%+170.68% 4.84TCr
-3.25%+2.62%+54.36%-17.92% 3.27TCr
-0.97%+5.34%+48.86%+98.66% 2.6TCr
+3.00%+5.91%+3.53%+221.78% 2.18TCr
-0.90%+3.73%+65.14%+125.73% 1.71TCr
Average -2.55%+24.26%+64.80%+69.77% 4.53TCr
Weighted average by Cap. -4.06%+34.72%+82.27%+46.96%

Financials

2027 *2028 *
Net sales 1.57TCr 1.34TCr 1.25TCr 1.15TCr 2.16TCr 1,50200Cr 2.21TCr 15TCr 5.8TCr 75TCr 5.9TCr 5.77TCr 2,49300Cr 1.62TCr 1.39TCr 1.3TCr 1.19TCr 2.24TCr 1,55300Cr 2.28TCr 15TCr 6TCr 78TCr 6.09TCr 5.96TCr 2,57700Cr
Net income 281.8Cr 241.27Cr 225.11Cr 206.56Cr 388.14Cr 27TCr 395.78Cr 2.67TCr 1.04TCr 14TCr 1.06TCr 1.04TCr 45TCr 315.57Cr 270.19Cr 252.09Cr 231.32Cr 434.66Cr 30TCr 443.22Cr 2.99TCr 1.17TCr 15TCr 1.18TCr 1.16TCr 50TCr
Net Debt 912.92Cr 781.64Cr 729.28Cr 669.19Cr 1.26TCr 87TCr 1.28TCr 8.65TCr 3.37TCr 44TCr 3.43TCr 3.35TCr 1,44900Cr 873.21Cr 747.64Cr 697.56Cr 640.08Cr 1.2TCr 84TCr 1.23TCr 8.28TCr 3.23TCr 42TCr 3.28TCr 3.21TCr 1,38600Cr
Logo CSL Limited
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-